# Ipamorelin Dosage in Research: Doses, Routes, and Half-Life

> Ipamorelin dosage as studied — the human IV doses, rodent SC ranges, routes, and the ~2-hour half-life that shapes timing. Research context only; no human dosing advice.

The doses and routes that show up in the published studies — described third-person, with the kinetics that make timing the central question. No human dosing guidance.

## Read this first

This page describes what doses of ipamorelin researchers gave, to which species, by which route — and nothing more. It is not a how-to and contains no recommended human dose. That boundary matters here because ipamorelin is not an approved medicine and the only completed human trial used it by vein in a hospital, twice daily, for up to a week [2]. The thread that ties the doses together is pharmacokinetics: ipamorelin's level falls by half about every two hours and the growth-hormone pulse it triggers peaks near 40 minutes, so when a dose is given matters more than holding a steady blood level [1]. Below are the study doses, the routes that have been tested, what the half-life implies for timing, and a plain note on the cjc-1295 ipamorelin question — always as research context, never as instruction.

## Doses that appear in the studies

In the human PK/PD study, healthy volunteers received single IV doses of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes [1]. The Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [2]. Rodent work spans a wide range: rat bone-growth studies used 18, 90, and 450 microg/day subcutaneously, divided three times daily over 15 days [4]; the 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. These are species- and model-specific experimental doses — they do not convert to a human protocol, and none is presented here as one.

## Routes that have been studied

Intravenous administration carries the human PK and clinical-trial data and much of the rodent efficacy work [1][2]. Subcutaneous injection dominates the rodent bone and body-composition studies — and is also the dominant route in off-label community use, though that use has no published human PK or safety characterization [4]. Intraperitoneal dosing appears in rodent and ferret efficacy studies [5]. Oral administration is effectively a dead end for ipamorelin itself: it is not orally bioavailable, and oral activity belongs only to engineered analogs such as NN703 (~30% in dogs) built specifically to overcome that [10][11].

## What the half-life implies for timing

Ipamorelin's terminal half-life is about 2 hours in humans, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [1]. The GH pulse it triggers peaks near 40 minutes and then subsides as a single discrete event [1]. The practical consequence in the research literature is that ipamorelin is studied as a pulse generator, not a continuous-level drug — its short residence means each dose produces a brief, self-limiting GH burst rather than a sustained elevation. Full detail of the elimination time-course is on the [how long does ipamorelin stay in your system](/half-life) page.

## How to reconstitute cjc-1295 ipamorelin 5mg

In the research-supply literature, ipamorelin is handled as a lyophilized (freeze-dried) powder — free base or acetate salt — reconstituted with bacteriostatic water before use. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically refrigerated. These are general peptide-handling observations from the research-supply context, not a clinical preparation instruction and not a protocol — this site provides no reconstitution recipe, dose, or volume for human use, and the only documented human administration of ipamorelin was intravenous and clinician-supervised [2].

## How much cjc-1295 ipamorelin should i take

This digest gives no answer to how much cjc-1295 ipamorelin a person should take, because no controlled human trial of the combination establishes any dose for any outcome [2]. The community 'stack' protocols that pair the two subcutaneously have no peer-reviewed human dosing basis and are described in the literature as anecdotal, not recommended [2]. What the evidence does support is mechanistic: GHRH-analog-plus-secretagogue co-administration raises GH synergistically at the class level [13]. That is a statement about pharmacology, not a personal dose — and nothing on this page should be read as one.

---

An editorial digest that reads ipamorelin through its kinetics — half-life, clearance, and a single GH pulse, each figure traced to the study that measured it; this is not a pharmacy, it dispenses nothing, and nothing here is a dose or a recommendation.